Importantly, both strategies have been translated into efficacious obesity pharmacotherapies when combined with GLP‐1R agonism; tirzepatide, a marketed GIPR/GLP‐1R dual agonist and maridebart cafraglutide, a GIPR antagonist/GLP‐1R agonist currently in phase III clinical trials.11, 12. Here, GIPR is linked to obesity disorder.